This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Antidepressant Dosing and Switching Guidelines: Focus on Nefazodone

John Zajecka, MD; Geoffry W. McEnany, RN, PhD, CS; and Kimberly M. Lusk, PharmD, BCPP

Published: January 1, 2002

Article Abstract

Dosing strategies form a fulcrum between patient-related and provider-related dimensions of treatment. The former focus on perceptions of efficacy and safety and adherence to the regimen, whereas the latter focus on symptom identification and appropriate drug selection. Appropriate dosing strategies may modulate adverse effects, allowing the patient to move more comfortably toward an efficacious response. Dosing also is an important dimension in switching between 2 antidepressants when the efficacy of the first agent is suboptimal. Nefazodone is effective for the management of acute, severe, and chronic major depression and relapse prevention. Response rates with nefazodone are comparable to those of imipramine and most SSRIs. In clinical trials, the efficacy of nefazodone was most clearly established at doses between 300 and 600 mg/day. At this dose range, discontinuations because of adverse events are low.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 63

Quick Links: